Our results reveal a novel mechanism of acquired trastuzumab resistance mediated by two pivotal effectors of the Hippo tumor suppressor pathway: the transcriptional co-activator YAP1 and the transcription factors TEAD1-2. The gene discussed is YAP1; the disease is neoplasm.